Key result
Panax notoginseng triol saponins showed stronger anti-platelet aggregation effects than total saponins in MCAO model rats, likely by reducing VWF-mediated platelet adhesion via GP1BA regulation.
Why the study?
Panax notoginseng triol saponins has been used clinically for ischemic stroke therapy in China, but its mechanisms remain unclear.
Does Panax notoginseng triol saponins (PTS) improve anti-platelet aggregation and reduce infarct size in MCAO model rats?
Does Panax notoginseng triol saponins (PTS) improve anti-platelet aggregation and reduce infarct size in MCAO model rats?
PTS demonstrates anti-platelet aggregation and anti-thrombotic effects in an ischemic stroke rat model, likely mediated by GP1BA regulation.
May inform PTS as antiplatelet candidate in stroke models; leaves open translation to human patients.
Background: Panax notoginseng triol saponins (PTS) has been used clinically for ischemic stroke therapy (IST) by potential anti-platelet aggregation and neuro-protective in China for more than sixteen years, but its mechanisms are still unclear. In this study, anti-platelet aggregation related protein analysis and computer simulations of drug-protein binding interactions were performed for exploring mechanism of PTS against ischemic stroke by ischemia reperfusion model. Methods: Three doses of PTS were administered orally in middle cerebral artery occlusion (MCAO) model rats; Panax notoginseng total saponins (PNS) and the combination of PTS and aspirin were chosen as comparison. The cerebral infarct size and water content in brain tissue, histomorphological observation, related factors and platelet receptor expression in serum, as well as binding affinity of PTS and platelet adhesion receptor were detected to evaluate therapeutic effect and explore possible mechanisms of anti-platelet aggregation. Results: Compared with PNS, PTS showed stronger and more extensive anti-platelet aggregation effect on MCAO model rats. The combination of PTS and aspirin might reduce the gastrointestinal adverse reactions by regulating TXA 2 /PGI 2 ratio. However, PTS could reduce the chance of VWF-mediated platelet adhesion to damaged vascular endothelium, and thus enhance the probability of anti-platelet aggregation and anti-thrombosis under pathological conditions. Conclusion: Our results showed that GP1BA was closely related with anti-platelet aggregation action of PTS, which provided new scientific evidences for its clinical application.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) studied Ischemic stroke. Panax notoginseng triol saponins (PTS) vs. Panax notoginseng total saponins (PNS) and combination of PTS and aspirin was evaluated on Anti-platelet aggregation effect, cerebral infarct size, and water content. Panax notoginseng triol saponins showed stronger anti-platelet aggregation effects than total saponins in MCAO model rats, likely by reducing VWF-mediated platelet adhesion via GP1BA regulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: